Analysts’ Viewpoint on Triclabendazole Market Scenario
Telehealth and eHealth services are changing the triclabendazole market landscape amid the ongoing COVID-19 pandemic. However, the launch of vaccines for fasciolas species is affecting sales of triclabendazole therapeutics. Hence, healthcare companies in the veterinary segment should tap revenue opportunities and diversify their focus on dairy and protein products sector. While using triclabendazole, veterinarians are educating animal owners to choose efficient treatment plans for using drugs that target the stage of the disease. It has been found that triclabendazole is relatively effective against the very early stages of the infection in animals.
The ever-expanding dairy industry is creating revenue opportunities for companies in the triclabendazole market. The high demand for quality milk and protein products is translating into revenue opportunities for triclabendazole medicine manufacturers. As such, manufacturers are increasing output capacities in the form of tablet and oral suspensions.
Cost-effective production of safe and high quality animal protein is necessary to meet consumer needs. Healthcare companies in the triclabendazole market are taking advantage of this trend to increase the availability of therapeutics in veterinary hospitals, clinics, pharmacies, and drug stores. Moreover, eCommerce holds promising potentials to expand revenue streams.
Manufacturers in the triclabendazole market are increasing local production capabilities to reduce dependence on other countries for veterinary medical supplies. Manufacturers are working at breakneck speeds to increase the availability for life-saving therapeutics. In the veterinary landscape, elective procedures have been postponed indefinitely. Such findings are affecting revenue generation activities in the triclabendazole market. Nevertheless, manufacturers are ensuring business continuity by maintaining optimum inventory levels.
Companies in the triclabendazole market are rethinking supply networks during the ongoing pandemic, owing to logistic challenges. Although poor demand sentiments are affecting income sources of healthcare companies, participants in the market are establishing balanced relationship with suppliers and ecosystem partners to keep economies running. They are strategizing over marketing and distribution activities to revive revenue sources.
Veterinarians are gaining cognizance about side effects and precautions of triclabendazole such as possible abdominal pain amongst animals and reading the label for non-prescription medicines. Triclabendazole is being extensively used for treating fascioliasis, which is caused by the liver fluke parasite namely fasciola hepatica. The high incidence of animals eating contaminated water plants such as watercress or algae is leading to increased morbidity and mortality in animals due to fascioliasis. Manufacturers are boosting their production capabilities for triclabendazole medications to support treatment of fascioliasis in animals.
Government initiatives are contributing to the management of liver fluke infections. Such initiatives are evident in countries such as Western Australia (WA), owing to the absence of liver fluke in the country. Moreover, potential carrier animals imported in WA are subject to mandatory testing. Thus, treatment provisions are being made by maintaining robust supply of triclabendazole medicines to ensure freedom from liver fluke.
The annual cost of liver fluke disease is estimated to be US$ 1 Bn in Australia and US$ 7.11 Bn in Brazil. Hence, manufacturers in the triclabendazole market are ensuring a continuous supply of therapeutics in veterinary healthcare facilities to reduce the treatment burden on the government and other participants in the value chain.
Growing awareness about the efficacy of triclabendazole for the treatment of liver fluke disease is contributing to market growth. Healthcare companies in the triclabendazole market are capitalizing on this opportunity to boost production capacities, since this disease causes significant financial losses to producers in value chains such as meat, dairy, and other industries.
Cattle and sheep are fueling the demand for triclabendazole medicines. Veterinarians are educating and creating awareness among animal owners about effective treatment and control on farms by helping them acquire a better understanding of the infection cycle. This is necessary since the weather has a significant effect on the prevalence of liver fluke in cattle and sheep.
|
Attribute |
Detail |
|
Market Size Value in 2020 |
US$ 412 Mn |
|
Market Forecast Value in 2031 |
US$ 632.1 Mn |
|
Growth Rate (CAGR) |
4.1% |
|
Forecast Period |
2021–2031 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
Triclabendazole market is expected to reach the value of US$ 632.1 Mn by 2031
Triclabendazole market to expand at a CAGR of 4.1% from 2021 to 2031
Triclabendazole market is driven by rise in demand for improved nutrition, particularly animal protein, and increase in focus on food safety.
The veterinary hospitals segment dominated the market, accounting for 26.4% share in 2020 and the trend is projected to continue during the forecast period.
Key players operating in the global market include AdvaCare Pharma, RV Lifesciences Limited, Grampus Laboratories, Intas Pharmaceuticals Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Triclabendazole Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Triclabendazole Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Prevalence rate of Fasciola hepatica in animal health
5.2. Sales Volume of Triclabendazole (Best effort Basis)
5.3. Pricing Analysis
5.4. Regulatory Scenario by Region/globally
5.5. COVID-19 Impact Analysis
6. Global Triclabendazole Market Analysis and Forecast, by Dosage Form
6.1. Introduction & Definition
6.1.1. Key Findings / Developments
6.2. Global Triclabendazole Market Value Forecast, by Dosage Form, 2017–2031
6.2.1. Tablet
6.2.2. Oral Suspension
6.3. Global Triclabendazole Market Attractiveness, by Dosage Form
7. Global Triclabendazole Market Analysis and Forecast, by Animal Type
7.1. Introduction & Definition
7.1.1. Key Findings / Developments
7.2. Global Triclabendazole Market Value Forecast, by Animal Type, 2017–2031
7.2.1. Cattle
7.2.2. Sheep
7.2.3. Goat
7.2.4. Others
7.3. Global Triclabendazole Market Attractiveness, by Animal Type
8. Global Triclabendazole Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.1.1. Key Findings / Developments
8.2. Global Triclabendazole Market Value Forecast, by Distribution Channel, 2017–2031
8.2.1. Veterinary Hospitals
8.2.2. Veterinary Clinics
8.2.3. Pharmacies & Drug Stores
8.2.4. Others
8.3. Global Triclabendazole Market Attractiveness, by Distribution Channel
9. Global Triclabendazole Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Triclabendazole Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. North America Triclabendazole Market Attractiveness, by Region
10. North America Triclabendazole Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
10.2.1. Tablet
10.2.2. Oral Suspension
10.3. North America Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
10.3.1. Cattle
10.3.2. Sheep
10.3.3. Goat
10.3.4. Others
10.4. North America Triclabendazole Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Veterinary Hospitals
10.4.2. Veterinary Clinics
10.4.3. Pharmacies & Drug Stores
10.4.4. Others
10.4.5. North America Triclabendazole Market Attractiveness, by Distribution Channel
10.5. North America Triclabendazole Market Value (US$ Mn) Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. North America Triclabendazole Market Attractiveness Analysis
10.6.1. By Dosage Form
10.6.2. By Animal Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Triclabendazole Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
11.2.1. Tablet
11.2.2. Oral Suspension
11.3. Europe Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
11.3.1. Cattle
11.3.2. Sheep
11.3.3. Goat
11.3.4. Others
11.4. Europe Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
11.4.1. Germany
11.4.2. U.K.
11.4.3. France
11.4.4. Spain
11.4.5. Italy
11.4.6. Rest of Europe
11.5. Europe Triclabendazole Market Attractiveness Analysis
11.5.1. By Dosage Form
11.5.2. By Animal Type
11.5.3. By Distribution Channel
11.5.4. By Country/Sub-region
12. Asia Pacific Triclabendazole Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
12.2.1. Tablet
12.2.2. Oral Suspension
12.3. Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
12.3.1. Cattle
12.3.2. Sheep
12.3.3. Goat
12.3.4. Others
12.4. Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
12.4.1. China
12.4.2. Japan
12.4.3. India
12.4.4. Australia & New Zealand
12.4.5. Rest of Asia Pacific
12.5. Asia Pacific Triclabendazole Market Attractiveness Analysis
12.5.1. By Dosage Form
12.5.2. By Animal Type
12.5.3. By Distribution Channel
12.5.4. By Country/Sub-region
13. Latin America Triclabendazole Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
13.2.1. Tablet
13.2.2. Oral Suspension
13.3. Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
13.3.1. Cattle
13.3.2. Sheep
13.3.3. Goat
13.3.4. Others
13.4. Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of Latin America Latin America
13.5. Latin America Triclabendazole Market Attractiveness Analysis
13.5.1. By Dosage Form
13.5.2. By Animal Type
13.5.3. By Distribution Channel
13.5.4. By Country/Sub-region
14. Middle East & Africa Triclabendazole Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
14.2.1. Tablet
14.2.2. Oral Suspension
14.3. Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
14.3.1. Cattle
14.3.2. Sheep
14.3.3. Goat
14.3.4. Others
14.4. Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
14.4.1. GCC Countries
14.4.2. South Africa
14.4.3. Rest of Middle East & Africa
14.5. Middle East & Africa Triclabendazole Market Attractiveness Analysis
14.5.1. By Dosage Form
14.5.2. By Animal Type
14.5.3. By Distribution Channel
14.5.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by Tier and Size of companies)
15.2. Market Share / Position Analysis, by Company, 2020
15.3. Competitive Business Strategies
15.4. Company Profiles
15.4.1. AdvaCare Pharma
15.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.1.2. Financial Analysis
15.4.1.3. Growth Strategies
15.4.1.4. SWOT Analysis
15.4.2. RV Lifesciences Limited
15.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.2.2. Financial Analysis
15.4.2.3. Growth Strategies
15.4.2.4. SWOT Analysis
15.4.3. Grampus Laboratories
15.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.3.2. Financial Analysis
15.4.3.3. Growth Strategies
15.4.3.4. SWOT Analysis
15.4.4. Intas Pharmaceuticals Ltd
15.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.4.2. Financial Analysis
15.4.4.3. Growth Strategies
15.4.4.4. SWOT Analysis
15.4.5. Shanghai Tongren Pharmaceutical Co., Ltd.
15.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.5.2. Financial Analysis
15.4.5.3. Growth Strategies
15.4.5.4. SWOT Analysis
15.4.6. Shijiazhuang Shimu Animal Pharmaceutical Co., Ltd.
15.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.6.2. Financial Analysis
15.4.6.3. Growth Strategies
15.4.6.4. SWOT Analysis
15.4.7. Siflon Drugs & Pharmaceuticals Pvt. Ltd.
15.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.7.2. Financial Analysis
15.4.7.3. Growth Strategies
15.4.7.4. SWOT Analysis
15.4.8. Elanco
15.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.8.2. Financial Analysis
15.4.8.3. Growth Strategies
15.4.8.4. SWOT Analysis
15.4.9. Virbac
15.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.9.2. Financial Analysis
15.4.9.3. Growth Strategies
15.4.9.4. SWOT Analysis
15.4.10. Bimeda, Inc.
15.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.10.2. Financial Analysis
15.4.10.3. Growth Strategies
15.4.10.4. SWOT Analysis
15.4.11. Chanelle Pharma
15.4.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.11.2. Financial Analysis
15.4.11.3. Growth Strategies
15.4.11.4. SWOT Analysis
15.4.12. Zoetis Health
15.4.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.12.2. Financial Analysis
15.4.12.3. Growth Strategies
15.4.12.4. SWOT Analysis
List of Tables
Table 01: Global Triclabendazole Market Volume (000 Unit) Forecast, by Oral Suspension, 2017–2031
Table 02: Global Triclabendazole Market Volume (000 Unit) Forecast, by Tablet, 2017–2031
Table 03: Global Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 04: Global Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
Table 05: Global Triclabendazole Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 06: Global Triclabendazole Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 08: North America Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 09: North America Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
Table 10: North America Triclabendazole Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 11: Europe Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 13: Europe Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
Table 14: Europe Triclabendazole Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 15: Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 17: Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
Table 18: Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 19: Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 21: Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
Table 22: Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 23: Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 24: Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 25: Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
Table 26: Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Triclabendazole Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 02: Global Triclabendazole Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 03: Global Triclabendazole Market Value (US$ Mn), by Tablet, 2017–2031
Figure 04: Global Triclabendazole Market Value (US$ Mn), by Oral Suspension, 2017–2031
Figure 05: Global Triclabendazole Market Value Share Analysis, by Animal Type, 2020 and 2031
Figure 06: Global Triclabendazole Market Attractiveness Analysis, by Animal Type, 2021–2031
Figure 07: Global Triclabendazole Market Value (US$ Mn), by Cattle, 2017–2031
Figure 08: Global Triclabendazole Market Value (US$ Mn), by Sheep, 2017–2031
Figure 09: Global Triclabendazole Market Value (US$ Mn), by Goat, 2017–2031
Figure 10: Global Triclabendazole Market Value (US$ Mn), by Others, 2017–2031
Figure 11: Global Triclabendazole Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 12: Global Triclabendazole Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 13: Global Triclabendazole Market Value (US$ Mn), by Veterinary Hospitals, 2017–2031
Figure 14: Global Triclabendazole Market Value (US$ Mn), by Veterinary Clinics, 2017–2031
Figure 15: Global Triclabendazole Market Value (US$ Mn), by Pharmacies & Drug Stores, 2017–2031
Figure 16: Global Triclabendazole Market Value (US$ Mn), by Others, 2017–2031
Figure 17: Global Triclabendazole Market Value Share Analysis, by Region, 2020 and 2031
Figure 18: Global Triclabendazole Market Attractiveness Analysis, by Region, 2021–2031
Figure 19: North America Triclabendazole Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 20: North America Triclabendazole Market Value Share, by Country, 2020–2031
Figure 21: North America Triclabendazole Market Attractiveness Analysis, by Country, 2021–2031
Figure 22: North America Triclabendazole Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 23: North America Triclabendazole Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 24: North America Triclabendazole Market Value Share Analysis, by Animal Type, 2020 and 2031
Figure 25: North America Triclabendazole Market Attractiveness Analysis, by Animal Type, 2021–2031
Figure 26: North America Triclabendazole Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 27: North America Triclabendazole Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 28: Europe Triclabendazole Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 29: Europe Triclabendazole Market Value Share, by Country/Sub-region, 2020–2031
Figure 30: Europe Triclabendazole Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 31: Europe Triclabendazole Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 32: Europe Triclabendazole Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 33: Europe Triclabendazole Market Value Share Analysis, by Animal Type, 2020 and 2031
Figure 34: Europe Triclabendazole Market Attractiveness Analysis, by Animal Type, 2021–2031
Figure 35: Europe Triclabendazole Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 36: Europe Triclabendazole Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 37: Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 38: Asia Pacific Triclabendazole Market Value Share, by Country/Sub-region, 2020–2031
Figure 39: Asia Pacific Triclabendazole Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 40: Asia Pacific Triclabendazole Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 41: Asia Pacific Triclabendazole Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 42: Asia Pacific Triclabendazole Market Value Share Analysis, by Animal Type, 2020 and 2031
Figure 43: Asia Pacific Triclabendazole Market Attractiveness Analysis, by Animal Type, 2021–2031
Figure 44: Asia Pacific Triclabendazole Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 45: Asia Pacific Triclabendazole Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 46: Latin America Triclabendazole Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 47: Latin America Triclabendazole Market Value Share, by Country/Sub-region, 2020–2031
Figure 48: Latin America Triclabendazole Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 49: Latin America Triclabendazole Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 50: Latin America Triclabendazole Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 51: Latin America Triclabendazole Market Value Share Analysis, by Animal Type, 2020 and 2031
Figure 52: Latin America Triclabendazole Market Attractiveness Analysis, by Animal Type, 2021–2031
Figure 53: Latin America Triclabendazole Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 54: Latin America Triclabendazole Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 55: Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 56: Middle East & Africa Triclabendazole Market Value Share, by Country/Sub-region, 2020–2031
Figure 57: Middle East & Africa Triclabendazole Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 58: Middle East & Africa Triclabendazole Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 59: Middle East & Africa Triclabendazole Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 60: Middle East & Africa Triclabendazole Market Value Share Analysis, by Animal Type, 2020 and 2031
Figure 61: Middle East & Africa Triclabendazole Market Attractiveness Analysis, by Animal Type, 2021–2031
Figure 62: Middle East & Africa Triclabendazole Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 63: Middle East & Africa Triclabendazole Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Triclabendazole Market
